Santé Canada Health Canada

Biologics and Genetic Therapies Directorate

Drug Submission Performance Quarterly Report

October-December

2017

Canada

Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. We assess the safety of drugs and many consumer products, help improve the safety of food, and provide information to Canadians to help them make healthy decisions. We provide health services to First Nations people and to Inuit communities. We work with the provinces to ensure our health care system serves the needs of Canadians.

Également disponible en français sous le titre :
Direction des produits biologiques et des thérapies génétiques – Rapport trimestriel du rendement des présentations de drogue – Octobre – Décembre 2017

To obtain additional information, please contact:

Health Canada
Address Locator 0202A1
101 Tunney's Pasture Driveway, Tunney's Pasture
Ottawa, Ontario
K1A 0K9
Tel.: 613-941-7281
Fax: 613-941-0825
E-mail: publications@hc-sc.gc.ca

Publication date: February 2018

Cat H2-2E-PDF
ISSN 2561-5572
Pub 170450

Table of Contents

OVERVIEW

The Biologics and Genetic Therapies Directorate (BGTD) Quarterly Drug Submission Performance Report reflects biologic and radiopharmaceutical drug submission review activity over five consecutive quarters: from October – December 2016 to October – December 2017. Statistics are provided by Submission Type and show the number received the number in workload, the number of decisions and the number of approvals.

General Information

There are several steps involved in the drug submission review[1] and approval process:

- administrative processing,
- regulatory and scientific screening and
- in-depth scientific review.

When deficiencies or non-compliance issues are found, a company may submit responses before a final decision can be reached and thus multiple review cycles may be required. A submission's approval time can vary depending on the number and type of review cycles needed.

Submissions Received are counts of submissions received during the year using the filing date (CR date) which is the date the submission is considered administratively complete by Health Canada.

Workload is the number of submissions "under active review" on the last day of the quarter. **"Backlog"** is the proportion of the workload that is over target. Often the term workload is used to mean the amount of work received over a period of time and is a common source of confusion.

Approvals[2] are Notice of Compliances (NOC) Issued or Issuable. An NOC issuable is when a submission's NOC is placed "on hold" awaiting authorization to market, due to Patented Medicines (NOC) Regulations or due to changes from Prescription to Non-Prescription.

[1] For further clarification refer to the Guidance for Industry: Management of Drug Submissions

[2] Final results from confirmatory trials submitted in the form of an SNDS-C are now included in the SNDS Received, Workload and Performance figures. SNDS-C are not included in the SNDS Approval figures. For further Clarification refer to to the Guidance Document: Notice of Compliance with Conditions (NOC/c).

A **review cycle completion**[3] is counted upon the conclusion of an in-depth scientific review that then results in a decision of approval or non-approval. The time taken is compared to a set performance standard[4] which is based on the type of submission, class and cycle (status). For example, in the case of a Priority NDS, the performance standard is 180 days for Review1 and 90 days for Review2. Health Canada has set a goal of 90% of review cycle completions to be rendered within performance standards.

"First Cycle Review" Approvals are those submissions approved without having to go through several review cycles to resolve submission deficiencies or non-compliance issues, and exclude "refiled"[5] submissions.

Any questions or comments on this report should be forwarded to:

Office of Submissions and Intellectual Property, Biologics and Genetics Therapies Directorate

Finance Building, A.L. # 0202A1
101 Tunney's Pasture Driveway, Tunney's Pasture
Ottawa, Ontario, K1A 0K9

Tel: (613) 941-7281 Fax: (613) 941-0825

Email: hc.sipdmail.sc@canada.ca

[3] Review cycles include all types e.g. Review 1, Review 2, Review QN. The total number of "review decisions" may surpass the total number of review cycle completions as they include cancellations/withdrawals that occur while the submission is 'inactive'. For example, a withdrawal can be issued when a company fails to respond to a notice of non-compliance within the allotted time frame. A 'Cancelled by Company' is counted as a review decision when a company sends a cancellation letter after the submission's original materials have been accepted for review.

[4] Performance continues to be measured against performance standards for Submission Type/Submission Class/ Status combinations as set out in Appendix 3 of the Guidance for Industry: Management of Drug Submissions .This is not to be confused with the 'UF Review 1 (iteration 1)' performance standards that are employed to measure performance to meet the *User Fees Act* reporting Requirements in the 'Health Canada Departmental Performance Report (DPR).

[5] For further clarification refer to the Guidance for Industry: Management of Drug Submissions

ACRONYMS

Submission Types

CTA	-	Clinical Trial Application
CTA-A	-	Clinical Trial Application-Amendment
DINB	-	Application for a Drug Identification Number - Biological Product
MP-NDS		Pre- New Drug Submission Meeting
MP-SNDS		Pre- Supplemental New Drug Submission Meeting
NDS	-	New Drug Submission
NC	-	Notifiable Change (Level II) – New Drug
PDC	-	Post Din Changes
PRNDS	-	Request for Priority Review Status: New Drug Submission
PRSNDS	-	Request for Priority Review Status: Supplemental New Drug Submission
SNDS	-	Supplemental New Drug Submission
SNDS-C	-	Supplemental New Drug Submission – CONFIRMATORY
YBPR	-	Yearly Biologic Product Report

Documents

NOC	-	Notice of Compliance
NOC-c	-	Notice of Compliance with Conditions
Issuable NOC (Patent)	-	NOC on Hold due to Patented Medicines (NOC) Regulations
Issuable NOC (Rx to OTC)	-	NOC on Hold due to changes (Rx to OTC)
NON	-	Notice of Non-Compliance
NOD	-	Notice of Deficiency
NON Withdrawal	-	Notice of Non-Compliance Withdrawal Letter
NOD Withdrawal	-	Notice of Deficiency Withdrawal Letter

Fee Categories

Fee Category	Fee Category Description
New Active Substance (NAS)	Submission in support of a drug, excluding a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada, and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph. For biologics, this submission class does not include an NDS in support of a subsequent entry biologic or an SNDS in support of changes to the manufacturing process of biologics.
Clinical or Non-Clinical Data and Chemistry and Manufacturing data	Submissions based on clinical or non-clinical data **and** chemistry and manufacturing data for a drug that does not include a NAS.
Clinical or Non-Clinical Data Only	Submissions based only on clinical or non-clinical data for a drug that does not include a NAS.
Comparative Studies	Submissions based on comparative studies with or without chemistry and manufacturing data for a drug that does not include a NAS. It excludes superiority and non-inferiority studies since they are clinical studies. It also excludes pharmaceutical equivalence studies since they are captured by the chemistry and manufacturing fee.
Chemistry and Manufacturing Data Only	Submissions based only on chemistry and manufacturing data for a drug that does not include a NAS.
Published Data Only	Submissions based only on published clinical or non-clinical data for a drug that does not include a NAS.
Switch from Prescription to Nonprescription Status	Submissions based only on data that support the modification or removal of a medicinal ingredient on the Prescription Drug List. This fee is limited to switches from prescription to nonprescription status when an identical claim is made for an existing drug.
Labelling Only[6]	Submissions of labelling material that do not include supporting clinical or non-clinical data or chemistry and manufacturing data.
Administrative Submission[7]	Submissions in support of a manufacturer or product name change.
Disinfectants[8]	Submissions and applications that include data in support of a disinfectant.
Drug Identification Number (DIN) - Labelling Standards	Applications attesting to compliance with a labelling standard or Category IV Monograph (DINF) for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data.

For further information refer to the Guidance Document - Fees for the Review of Drug Submissions and Applications

[6] For more information, please consult the Guidance Document: Question and Answers about Plain Language Labelling
[7] For additional information, please consult the "Changes in Manufacturer and/or Product Name Policy" (2015)
[8] The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported on in a separate NNHPD Drug Submission Performance Report.

New Drug Submissions (NDS)

&

Supplemental New Drug Submissions (SNDS)

SUBMISSIONS RECEIVED[9],[10]

New Drug Submissions (NDS) Received by Fee Category



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Labelling Only	1	0	0	0	1
Clinical or Non-Clin and C&M	4	5	4	8	7
Unassigned	0	1	0	0	0
New Active Substance	7	6	2	1	4
Total	12	12	6	9	12
Priority Class	1	0	0	0	1
NOC-C Class	0	3	0	2	0
Emergency Use NDS	1	1	0	0	1
Biosimilar	3	3	2	4	3

Supplemental New Drug Submissions (SNDS) Received by Fee Category



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Labelling Only	18	8	17	16	15
Chemistry & Manufacturing	18	11	12	18	16
Clinical or Non-Clin and C&M	2	1	3	2	1
Published Data Only	2	2	1	2	0
Clinical or Non-Clin Only	12	20	12	21	14
Comparative Studies	1	0	1	1	0
Total	53	42	46	60	46
Priority Class	1	2	0	0	1
NOC-C Class	1	1	1	1	0
SNDS Confirmatory	1	3	0	3	1
Biosimilar	0	0	3	3	0

[9] **Biosimilar**: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

[10] Submissions granted Priority Review Status or found eligible for advance NOC/c consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the Priority Review of Drug Submissions Policy , the Notice of Compliance with conditions (NOC/c) Guidance and the Management of Drug Submissions Guidance .

WORKLOAD

New Drug Submission (NDS) Review Workload / Backlog



Supplemental New Drug Submission (SNDS) Review Workload / Backlog



WORKLOAD

New Drug Submission (NDS) Review Workload by Fee Category

BGTD NDS All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
Clinical or Non-Clin Only	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	**12**	**11**	**17**	**22**	**21**
Backlog	*0*	*0*	*0*	*0*	*0*
New Active Substance	**10**	**14**	**21**	**18**	**8**
Backlog	*0*	*0*	*0*	*0*	*0*
Labelling Only	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Total	**22**	**25**	**38**	**40**	**29**
Non Backlog	**22**	**25**	**38**	**40**	**29**
Backlog	**0**	**0**	**0**	**0**	**0**
% in Backlog	**0%**	**0%**	**0%**	**0%**	**0%**
Priority (subset)	**1**	**1**	**1**	**1**	**1**
Backlog	*0*	*0*	*0*	*0*	*0*

Supplemental New Drug Submission (SNDS) Review Workload by Fee Category

BGTD SNDS All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
Comparative Studies	**1**	**1**	**2**	**1**	**1**
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	**20**	**28**	**22**	**17**	**23**
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin Only	**35**	**44**	**45**	**51**	**51**
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	**3**	**4**	**8**	**7**	**6**
Backlog	*0*	*0*	*0*	*0*	*0*
Published Data	**2**	**3**	**4**	**2**	**4**
Backlog	*0*	*0*	*0*	*0*	*0*
Labelling Only	**11**	**5**	**12**	**9**	**8**
Backlog	*0*	*0*	*0*	*0*	*0*
Total	**72**	**85**	**93**	**87**	**93**
Non Backlog	**72**	**85**	**93**	**87**	**93**
Backlog	**0**	**0**	**0**	**0**	**0**
% in Backlog	**0%**	**0%**	**0%**	**0%**	**0%**
Priority (subset)	**3**	**3**	**2**	**1**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
SNDS-C (Confirmatory)	**1**	**3**	**5**	**6**	**6**
Backlog	*0*	*0*	*0*	*0*	*0*

APPROVALS

11

New Drug Submission (NDS) Approvals by Fee Category and by NOC Type



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Labelling Only	2	0	0	0	0
Clinical or Non-Clin and C&M	2	4	3	3	3
New Active Substance	4	3	1	3	11
Total	8	7	4	6	14
Notice of Compliance	6	7	3	6	9
NOC with Conditions	0	0	1	0	4
NOC on Hold (Patent)	2	0	0	0	1
Priority Class	0	0	0	1	0
NOC-C Class	0	0	1	0	4
Biosimilar	2	0	1	0	3

Supplemental New Drug Submission (SNDS) Approvals by Fee Category & NOC Type



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Labelling Only	3	14	8	21	9
Comparative Studies	1	1	0	1	1
Chemistry & Manufacturing	14	9	17	24	9
Clinical or Non-Clin and C&M	5	1	0	2	2
Published Data Only	1	0	1	2	0
Clinical or Non-Clin Only	7	7	17	10	12
Total	31	32	43	60	33
Notice of Compliance	30	32	42	58	32
NOC with Conditions	1	0	1	1	1
NOC on Hold (Patent)	0	0	0	1	0
Priority Class	0	1	2	1	1
NOC-C Class	1	0	1	1	1
Biosimilar	0	1	0	3	2

11 Submissions granted Priority Review Status or found eligible for advance NOC/c consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the Priority Review of Drug Submissions Policy , the Notice of Compliance with conditions (NOC/c) Guidance and the Management of Drug Submissions Guidance .

This page is left blank intentionally.

REVIEW CYCLE DECISIONS

New Drug Submission (NDS) Review Decisions



NDS - Review Cycle Completions Showing Percentage Within Target



REVIEW CYCLE DECISIONS

Supplemental New Drug Submission (SNDS) Review Decisions



SNDS - Review Cycle Completions Showing Percentage Within Target



SCREENING CYCLE DECISIONS

New Drug Submission (NDS) Screening Decisions



NDS - Screening Cycle Completions Showing Percentage Within Target



SCREENING CYCLE DECISIONS

Supplemental New Drug Submission (SNDS) Screening Decisions



SNDS - Screening Cycle Completions Showing Percentage Within Target



Priority Review Status Requests (for NDS & SNDS)

Priority Review Status Requests Received



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
PR-NDS NAS	0	0	0	0	0
PR-NDS CLIN/C&M	0	0	0	0	0
PR-NDS CLIN ONLY	1	1	0	1	3
PR-SNDS C&M	0	0	0	0	0
PR-SNDS CLIN ONLY	2	2	0	1	4
Total	3	3	0	2	7

Priority Review Status Requests: Decisions Rendered



Priority Review Status Request: Performance



Notifiable Changes (NC)

NOTIFIABLE CHANGE

Submissions Received - Notifiable Change (NC)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Quality (90)	73	105	94	110	102
Safety (90)	25	27	25	17	19
Safety (120)	1	5	5	2	2
Total	99	137	124	129	123

Decision Documents by Class - Notifiable Change (NC)

NC - SAFETY (90)					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	8	26	30	19	17
REJECTION LETTER (SCR)	0	0	0	0	0
CANCELLED BY COMPANY	2	1	2	1	2
SCREENING DEFICIENCY NOTICE	1	0	0	1	0
NOT SATISFACTORY NOTICE	0	0	0	0	0
NC - HOLD (PATENT)	0	0	0	0	0

NC - QUALITY (90)					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	98	88	85	103	108
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	2	1	0	0	1
SCREENING DEFICIENCY NOTICE	5	0	1	1	0
CANCELLED BY COMPANY	6	0	4	2	2

NC - SAFETY (120)					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	4	3	8	0	2
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	1	0	0
CANCELLED BY COMPANY	0	0	1	0	1

NC - ADMINISTRATIVE					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	0	5	2	0	3
CANCELLED BY COMPANY	0	0	0	0	0

WORKLOAD

Notifiable Change (NC) SAFETY - Review Workload / Backlog



Notifiable Change (NC) QUALITY - Review Workload / Backlog



WORKLOAD

Notifiable Change (NC) SAFETY - Review Workload by Class

BGTD NC - SAFETY: REVIEW WORKLOAD AT END OF QUARTER					
FEE Category	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
SAFETY - 90 day	15	15	12	11	13
Backlog	*0*	*0*	*0*	*0*	*0*
SAFETY - 120 day	2	4	0	2	1
Backlog	*0*	*0*	*0*	*0*	*0*
Total	17	19	12	13	14
Non Backlog	17	19	12	13	14
BACKLOG	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%

Notifiable Change (NC) QUALITY - Review Workload by Class

BGTD NC - QUALITY: REVIEW WORKLOAD AT END OF QUARTER					
CLASS	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
QUALITY - 90 day	49	59	69	78	65
Backlog	*0*	*0*	*0*	*3*	*3*
Total	49	59	69	78	65
Non Backlog	49	59	69	75	62
BACKLOG	0	0	0	3	3
% in Backlog	0%	0%	0%	4%	5%

PERFORMANCE

REVIEW Completions by Class - Notifiable Change (NC)



SCREENING Completions by Class - Notifiable Changes (NC)



Administrative Submissions

Submissions in support of a manufacturer or product name change.

ADMINISTRATIVE SUBMISSIONS (with BGTD Review)

(such as product name change that requires a drug name review)

Administrative Submissions Received (with BGTD Review)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
DINB Administrative	0	0	1	0	8
NC Administrative	0	5	2	0	3
NDS Administrative	3	4	4	0	5
SNDS Administrative	0	0	0	0	0
TOTAL	3	9	7	0	16

Administrative Submission Approvals (with BGTD Review)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
NDS - ADMINISTRATIVE	0	3	8	0	2
SNDS - ADMINISTRATIVE	0	0	0	0	0
TOTAL	0	3	8	0	2

ADMINISTRATIVE SUBMISSIONS (Processed by OSIP)

(Product & Manufacturer Name Changes) (Admin NCs are for cross-referenced changes)

Administrative Submissions Received by Submission Type (OSIP)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
NDS	19	40	41	12	14
SNDS	2	5	5	2	5
ANDS	33	16	44	50	55
SANDS	10	13	13	10	10
NC	83	77	71	77	59
DINS	38	63	33	29	31
PDC	0	1	0	0	1
TOTAL	185	215	207	180	175

Administrative Submission Approvals (OSIP) - for NDS, SNDS, ANDS and SANDS



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
NDS	15	34	31	37	5
SNDS	3	3	3	6	5
ANDS	28	19	26	66	37
SANDS	7	15	16	14	7
Total	53	71	76	123	54

This page is left blank intentionally**.**

Clinical Trial Applications and Amendments

(CTA & CTA-A)

Clinical Trial Applications (CTA)

Number Received - Clinical Trial Application (CTA)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Phase 1 HEALTHY HUMAN-30	0	0	2	0	3
Phase 1 OTHER - 30 DAYS	18	12	11	5	16
Phase 1/2 - 30 DAYS	2	10	5	5	9
Phase 2 - 30 DAYS	24	25	26	23	15
Phase 2/3 - 30 DAYS	2	2	3	2	0
Phase 3 - 30 DAYS	39	40	37	24	42
Phase Other	1	4	4	4	1
Total	86	93	88	63	86

Decision Documents - Clinical Trial Application (CTA)

CTA					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	87	74	84	63	85
CANCELLED BY COMPANY	6	9	4	3	6
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	1	0	0	0

Performance – Clinical Trial Applications (CTA) Reviews - 30 Day Target



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Target MET	92	78	87	66	90
Target Not Met	0	0	0	0	0
Total	92	78	87	66	90
Percent within target	100%	100%	100%	100%	100%
Average days	25	26	26	27	27
Median days	27	28	28	28	28

Quarter (decision date)

Clinical Trial Application- Amendments (CTA-A)

Number Received - Clinical Trial Application Amendments (CTA-A)



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Phase 1 HEALTHY HUMAN-30	2	0	4	1	0
Phase 1 OTHER - 30 DAYS	24	28	29	33	37
Phase 1/2 - 30 DAYS	20	21	20	13	18
Phase 2 - 30 DAYS	47	58	47	41	39
Phase 2/3 - 30 DAYS	4	7	8	8	7
Phase 3 - 30 DAYS	109	138	126	101	81
Phase Other	15	11	6	14	10
Total	221	263	240	211	192

Decision Documents - Clinical Trial Application Amendments (CTA-A)

CTA-A					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	217	227	241	192	201
REJECTION LETTER (SCR)	4	6	4	4	3
CANCELLED BY COMPANY	3	9	3	14	2
NOT SATISFACTORY NOTICE	0	0	0	0	0

Performance – CTA-A Reviews - 30 Day Target



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Target MET	208	216	229	196	189
Target Not Met	0	0	1	0	0
Total	208	216	230	196	189
Percent within target	100%	100%	100%	100%	100%
Average days	22	20	22	23	23
Median days	23	21	25	26	27

DINB

Application for a Drug Identification Number

Biological Product

DINB: Application for a Drug Identification Number – BIOLOGICAL PRODUCT

Number Received - DINB



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Labelling Only	10	2	0	0	1
Chemistry & Manufacturing	1	1	0	0	1
Comparative Studies	0	0	0	0	0
Clinical or Non-Clin Only	0	0	0	0	0
Clinical or Non-Clin and C&M	0	0	0	0	0
Total	11	3	0	0	2

REVIEW WORKLOAD

Review Workload / Backlog - Showing Percentage in Backlog - DINB



Review Workload by Class - DINB

BGTD DINB All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
Labelling Only	**0**	**6**	**2**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	**2**	**1**	**2**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Comparative Studies	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Total	**2**	**7**	**4**	**0**	**0**
Non Backlog	**2**	**7**	**4**	**0**	**0**
Backlog	**0**	**0**	**0**	**0**	**0**
% in Backlog	**0%**	**0%**	**0%**	**0%**	**0%**

SCREENING WORKLOAD

Screening Workload / Backlog - Showing Percentage in Backlog - DINB



Screening Workload by Class - DINB

BGTD DINB All SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31
Labelling Only	**0**	**4**	**0**	**0**	**1**
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	**0**	**0**	**1**	**0**	**1**
Backlog	*0*	*0*	*0*	*0*	*0*
Comparative Studies	**0**	**0**	**0**	**0**	**0**
Backlog	*0*	*0*	*0*	*0*	*0*
Total	**0**	**4**	**1**	**0**	**2**
Non Backlog	**0**	**4**	**1**	**0**	*2*
BACKLOG	**0**	**0**	**0**	**0**	**0**
% in Backlog	**0%**	**0%**	**0%**	**0%**	**0%**

DECISION DOCUMENTS

Decision Documents – DINB by Class

DINB - Labelling Only					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	6	0	4	2	0

DINB - CLINICAL OR NON CLINICAL DATA					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0

DINB - CLINICAL OR NON CLINICAL DATA AND C&M					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	0

DINB - CHEMISTRY & MANUFACTURING					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTIFICATION FORM/DIN ISSUED	0	0	0	1	0
CANCELLED BY COMPANY	0	0	0	0	0

DINB - COMPARATIVE STUDIES					
DOCUMENT TYPE	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0

DINB - Administrative					
DOCUMENT TYPE	**Oct-Dec 2016**	**Jan-Mar 2017**	**Apr-Jun 2017**	**Jul-Sep 2017**	**Oct-Dec 2017**
NOTIFICATION FORM/DIN ISSUED	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	1

PERFORMANCE

Performance Review Cycle Completions Showing Percentage Within Target - DINB



Performance Screening Cycle Completions Showing Percentage Within Target - DINB



Post –Authorization Division 1 Changes - Biologics (PDC-B)

Post –Authorization Division 1 Changes - Biologics (PDC-B) Received



Yearly Biologic Product Reports (YBPR)

[12])

Yearly Biologic Product Report s (YBPR) Received



	Oct-Dec 2016	Jan-Mar 2017	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017
Centre for Radiopharmaceuticals and Biotherapeutics Evaluation	66	36	29	34	54
Centre for Biologics Evaluation	29	8	21	26	36
Office of Regulatory Affairs	0	0	0	0	0
TOTAL	95	44	50	60	90

[12] Yearly Biologic Product Report (YBPR) is a report that must be submitted annually by manufacturers of all Schedule D (Biologic) drugs. The report contains production information on both drug substance and drug product lots, including test methods and results, reasons for any recalls and corrective action taken, as well as other pertinent post-market information.

Appendix A: Pre-submission Meetings

[13]

Pre-submission Meetings Held / Feedback Provided



	PRE-NDS MEETING MPNDS	PRE-SNDS MEETING MPSNDS	PRE-NC MEETING MPNC	PRE CLINICAL TRIAL APPLICATION MEETING PRECTA	PRE-DIN MEETING MPDIN
OCT-DEC 16	14	8	0	15	0
JAN-MAR 17	13	9	1	6	0
APR-JUN 17	7	7	0	12	0
JUL-SEP 17	7	5	0	7	0
OCT-DEC 17	10	10	4	11	0

[13] Prior to filing a submission, the sponsor may request a pre-submission meeting to discuss the presentation of data in support of the submission: For further information, refer to the Guidance for Industry: Management of Drug Submissions